{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:22:39Z","timestamp":1794540159893,"version":"4.9.1"},"reference-count":280,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric Antigen Receptor (CAR)-T cell therapy has rapidly emerged as a groundbreaking approach in cancer treatment, particularly for hematologic malignancies. However, the application of CAR-T cell therapy in solid tumors remains challenging. This review summarized the development of CAR-T technologies, emphasized the challenges and solutions in CAR-T cell therapy for solid tumors. Also, key innovations were discussed including specialized CAR-T, combination therapies and the novel use of CAR-Treg, CAR-NK and CAR-M cells. Besides, CAR-based cell therapy have extended its reach beyond oncology to autoimmune disorders. We reviewed preclinical experiments and clinical trials involving CAR-T, Car-Treg and CAAR-T cell therapies in various autoimmune diseases. By highlighting these cutting-edge developments, this review underscores the transformative potential of CAR technologies in clinical practice.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1519671","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T01:10:41Z","timestamp":1736385041000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":92,"title":["CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity"],"prefix":"10.3389","volume":"15","author":[{"given":"Yaojie","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2018.03.001","article-title":"The application of CAR-T cell therapy in hematological Malignancies: advantages and challenges","volume":"8","author":"Zhao","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1038\/srep03571","article-title":"Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","article-title":"Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity","volume":"18","author":"Yu","year":"2019","journal-title":"Mol Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00018-021-04089-x","article-title":"Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy","volume":"79","author":"Duan","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.12.7647","article-title":"T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity","volume":"173","author":"Chmielewski","year":"2004","journal-title":"J Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-024-01258-8","article-title":"Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders","volume":"8","author":"Xia","year":"2024","journal-title":"Nat BioMed Eng"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"biomark Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.75660","article-title":"De novo-designed transmembrane domains tune engineered receptor functions","volume":"11","author":"Elazar","year":"2022","journal-title":"Elife"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/imr.2013.257.issue-1","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/imr.v290.1","article-title":"T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance","volume":"290","author":"Chandran","year":"2019","journal-title":"Immunol Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02085-z","article-title":"In vivo human T cell engineering with enveloped delivery vehicles","volume":"42","author":"Hamilton","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ymeth.2017.04.003","article-title":"Genome editing via delivery of Cas9 ribonucleoprotein","author":"DeWitt","year":"2017","journal-title":"Methods"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002229","article-title":"Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors","volume":"4","author":"Frank","year":"2020","journal-title":"Blood Adv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-017-0444-9","article-title":"Chimeric antigen receptor T cells: a novel therapy for solid tumors","volume":"10","author":"Yu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302023","article-title":"T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells","volume":"10","author":"Heuser","year":"2003","journal-title":"Gene Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.1.185","article-title":"two-signal model for the primary activation of precursor helper T cells","volume":"96","author":"Bretscher","year":"1999","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.144.5.1585","article-title":"Antigen presentation by resting B cells. Effectiveness at inducing T cell proliferation is determined by costimulatory signals, not T cell receptor occupancy","volume":"144","author":"Jenkins","year":"1990","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2210046","DOI":"10.1080\/21645515.2023.2210046","article-title":"Kymriah\u00ae (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy","volume":"19","author":"Awasthi","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.11504","article-title":"Yescarta: A new era for non-hodgkin lymphoma patients","volume":"12","author":"AlDallal","year":"2020","journal-title":"Cureus"},{"key":"B36","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological Malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/jcm13010070","article-title":"Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options","volume":"13","author":"Garc\u00eda-Sancho","year":"2023","journal-title":"J Clin Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B40","article-title":"Ciltacabtagene autoleucel (Carvykti) for multiple myeloma","volume":"64","year":"2022","journal-title":"Med Lett Drugs Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nri1248","article-title":"CD28-mediated co-stimulation: a quantitative support for TCR signalling","volume":"3","author":"Acuto","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04451-w","article-title":"Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R\/R B-ALL patients: a systematic review and meta-analysis","volume":"100","author":"Hu","year":"2021","journal-title":"Ann Hematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.04.016","article-title":"A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells","volume":"12","author":"Pul\u00e8","year":"2005","journal-title":"Mol Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/10408363.2019.1633512","article-title":"Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects","volume":"56","author":"Poorebrahim","year":"2019","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e013904","DOI":"10.1136\/bmjopen-2016-013904","article-title":"Third-generation CD28\/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol","volume":"6","author":"Tang","year":"2016","journal-title":"BMJ Open"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A phase I\/IIa trial using CD19-targeted third-generation CAR T Cells for lymphoma and leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discovery"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-hodgkin\u2019s lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0200","article-title":"Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD","volume":"3","author":"K\u00fcnkele","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.192","article-title":"Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 \u201csuper-stimulation","volume":"21","author":"Hombach","year":"2013","journal-title":"Mol Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nm1676","article-title":"T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection","volume":"13","author":"Stephan","year":"2007","journal-title":"Nat Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.10.009","article-title":"2B4 (CD244, SLAMF4) and CS1 (CD319, SLAMF7) in systemic lupus erythematosus and cancer","volume":"204","author":"Malaer","year":"2019","journal-title":"Clin Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.12.047","article-title":"Current challenges and emerging opportunities of CAR-T cell therapies","volume":"319","author":"Abreu","year":"2020","journal-title":"J Control Release"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.1997.tb00137.x","article-title":"Apheresis techniques and cellular immunomodulation","volume":"1","author":"Smith","year":"1997","journal-title":"Ther Apher"},{"key":"B61","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/imr.v290.1","article-title":"CAR T cells for brain tumors: Lessons learned and road ahead","volume":"290","author":"Akhavan","year":"2019","journal-title":"Immunol Rev"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr Opin Biotechnol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744823","article-title":"Advances in universal CAR-T cell therapy","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2","article-title":"[amp]]lsquo;Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00485-1","article-title":"Will allogeneic CAR T cells for CD19(+) Malignancies take autologous CAR T cells \u2018off the shelf\u2019","volume":"18","author":"DiNofia","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.254","article-title":"CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications","volume":"29","author":"K\u00f6hl","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B69","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S138765","article-title":"CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia","volume":"12","author":"Vairy","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"25","author":"O\u2019Leary","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1090","article-title":"Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma","volume":"18","author":"Anderson","year":"2022","journal-title":"Future Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006922","article-title":"Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma","volume":"6","author":"Iacoboni","year":"2022","journal-title":"Blood Adv"},{"key":"B75","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/d41573-022-00048-8","article-title":"FDA approves second BCMA-targeted CAR-T cell therapy","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discovery"},{"key":"B76","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/cancers15030663","article-title":"CAR-T: what is next","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0690-8","article-title":"Chimeric antigen receptor (CAR) T cells: lessons learned from targeting of CD19 in B-cell Malignancies","volume":"77","author":"Hay","year":"2017","journal-title":"Drugs"},{"key":"B78","doi-asserted-by":"publisher","first-page":"106036","DOI":"10.1016\/j.phrs.2021.106036","article-title":"Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies","volume":"175","author":"Zhang","year":"2022","journal-title":"Pharmacol Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell Malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022410118","article-title":"Targeting loss of heterozygosity for cancer-specific immunotherapy","volume":"118","author":"Hwang","year":"2021","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B86","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-018-0629-x","article-title":"T cell senescence and CAR-T cell exhaustion in hematological Malignancies","volume":"11","author":"Kasakovski","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001688","article-title":"Deletion of Cbl-b inhibits CD8(+) T-cell exhaustion and promotes CAR T-cell function","volume":"9","author":"Kumar","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2019.1698261","article-title":"Memory T cell, exhaustion, and tumor immunity","volume":"43","author":"Ando","year":"2020","journal-title":"Immunol Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.1.104","article-title":"Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain","volume":"172","author":"Finney","year":"2004","journal-title":"J Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0422","article-title":"In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)","volume":"71","author":"Song","year":"2011","journal-title":"Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.2019.8.issue-5","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Transl Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.609421","article-title":"The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory\/recurrent multiple myeloma","volume":"12","author":"Duan","year":"2021","journal-title":"Front Immunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3390\/cancers12071969","article-title":"Co-expression of IL-7 improves NKG2D-based CAR T cell therapy on prostate cancer by enhancing the expansion and inhibiting the apoptosis and exhaustion","volume":"12","author":"He","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121491","article-title":"T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy","volume":"129","author":"Yamamoto","year":"2019","journal-title":"J Clin Invest"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00803","article-title":"Augmenting the effectiveness of CAR-T cells by enhanced self-delivery of PD-1-neutralizing scFv","volume":"8","author":"Ping","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2281-2","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions","volume":"68","author":"Hu","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwy008","article-title":"Glycan-directed CAR-T cells","volume":"28","author":"Steentoft","year":"2018","journal-title":"Glycobiology"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.618387","article-title":"Befriending the hostile tumor microenvironment in CAR T-cell therapy","volume":"11","author":"Lindo","year":"2020","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh1962","article-title":"Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence","volume":"13","author":"Katsarou","year":"2021","journal-title":"Sci Transl Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40364-020-00237-w","article-title":"PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo","volume":"8","author":"Liao","year":"2020","journal-title":"biomark Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.011","article-title":"Masked chimeric antigen receptor for tumor-specific activation","volume":"25","author":"Han","year":"2017","journal-title":"Mol Ther"},{"key":"B104","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.1158\/1078-0432.CCR-19-0101","article-title":"Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-hodgkin\u2019s lymphoma","volume":"25","author":"Yan","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-018-0858-1","article-title":"Tumor microenvironment participates in metastasis of pancreatic cancer","volume":"17","author":"Ren","year":"2018","journal-title":"Mol Cancer"},{"key":"B106","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"B107","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/cancers11050674","article-title":"CAR T-cells targeting the integrin \u03b1nte and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid Malignancies","volume":"11","author":"Whilding","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948457","article-title":"CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma","volume":"50","author":"Liu","year":"2020","journal-title":"Eur J Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat Commun"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.628906","article-title":"Chemokine receptor CCR2b enhanced anti-tumor function of chimeric antigen receptor T cells targeting mesothelin in a non-small-cell lung carcinoma model","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11427-019-9665-8","article-title":"Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment","volume":"63","author":"Zhao","year":"2020","journal-title":"Sci China Life Sci"},{"key":"B112","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/1479-5876-11-187","article-title":"Treatment of Malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells","volume":"11","author":"Schuberth","year":"2013","journal-title":"J Transl Med"},{"key":"B113","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-016-5027-4","article-title":"Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors","volume":"59","author":"Zhang","year":"2016","journal-title":"Sci China Life Sci"},{"key":"B115","doi-asserted-by":"publisher","first-page":"119401","DOI":"10.1016\/j.biomaterials.2019.119401","article-title":"Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells","volume":"219","author":"Yong","year":"2019","journal-title":"Biomaterials"},{"key":"B116","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T&xa0;cell therapy and the tumor microenvironment: Current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol Ther - Oncolytics"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"105111","DOI":"10.1016\/j.phrs.2020.105111","article-title":"Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy","volume":"161","author":"Zhang","year":"2020","journal-title":"Pharmacol Res"},{"key":"B119","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","article-title":"Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy","volume":"21","author":"Wu","year":"2022","journal-title":"Mol Cancer"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-n receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther"},{"key":"B123","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-tuned erbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-021-01470-1","article-title":"Are chimeric antigen receptor T cells (CAR-T cells) the future in immunotherapy for autoimmune diseases","volume":"70","author":"Santamaria-Alza","year":"2021","journal-title":"Inflammation Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J Immunother"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discovery"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907","article-title":"Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide","volume":"11","author":"Jan","year":"2019","journal-title":"Sci Transl Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12896-019-0537-3","article-title":"Modulation of chimeric antigen receptor surface expression by a small molecule switch","volume":"19","author":"Juillerat","year":"2019","journal-title":"BMC Biotechnol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"key":"B135","doi-asserted-by":"publisher","first-page":"aab4077","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.817296","article-title":"CAR T cell therapy in primary brain tumors: current investigations and the future","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.phrs.2017.11.035","article-title":"CAR-T cells and combination therapies: What\u2019s next in the immunotherapy revolution","volume":"129","author":"Ramello","year":"2018","journal-title":"Pharmacol Res"},{"key":"B138","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.185","article-title":"Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma","volume":"21","author":"Hegde","year":"2013","journal-title":"Mol Ther"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.semcancer.2019.12.019","article-title":"Combining epigenetic and immune therapy to overcome cancer resistance","volume":"65","author":"Gomez","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"118297","DOI":"10.1016\/j.lfs.2020.118297","article-title":"PD-1\/PD-L1 axis importance and tumor microenvironment immune cells","volume":"259","author":"Lotfinejad","year":"2020","journal-title":"Life Sci"},{"key":"B144","doi-asserted-by":"publisher","first-page":"104258","DOI":"10.1016\/j.phrs.2019.104258","article-title":"Understanding and overcoming the resistance of cancer to PD-1\/PD-L1 blockade","volume":"145","author":"Shergold","year":"2019","journal-title":"Pharmacol Res"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000433","article-title":"Dual targeting of TGF-e and PD-L1 via a bifunctional anti-PD-L1\/TGF-\u03b2RII agent: status of preclinical and clinical advances","volume":"8","author":"Lind","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004128","article-title":"CD19-directed chimeric antigen receptor T cell therapy in Waldenstr\u00f6m macroglobulinemia: a preclinical model and initial clinical experience","volume":"10","author":"Palomba","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol Ther"},{"key":"B148","doi-asserted-by":"publisher","first-page":"108382","DOI":"10.1016\/j.clim.2020.108382","article-title":"Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological Malignancies","volume":"214","author":"Song","year":"2020","journal-title":"Clin Immunol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-019-00759-1","article-title":"EGFRvIII-CAR-T cells with PD-1 knockout have improved anti-glioma activity","volume":"26","author":"Zhu","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"key":"B152","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci Rep"},{"key":"B153","doi-asserted-by":"publisher","first-page":"109055","DOI":"10.1016\/j.intimp.2022.109055","article-title":"CRISPR\/Cas9-medaited knockout of endogenous T-cell receptor in Jurkat cells and generation of NY-ESO-1-specific T cells: An in vitro study","volume":"110","author":"Safarzadeh Kozani","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005185","article-title":"Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR","volume":"136","author":"Stenger","year":"2020","journal-title":"Blood"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00683","article-title":"Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment","volume":"11","author":"Shi","year":"2020","journal-title":"Front Immunol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00866","article-title":"Oncolytic viral therapy and the immune system: A double-edged sword against cancer","volume":"9","author":"Marelli","year":"2018","journal-title":"Front Immunol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02103","article-title":"Oncolytic viruses partner with T-cell therapy for solid tumor treatment","volume":"9","author":"Rosewell Shaw","year":"2018","journal-title":"Front Immunol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Res"},{"key":"B161","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.phrs.2017.05.004","article-title":"Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy","volume":"126","author":"Yang","year":"2017","journal-title":"Pharmacol Res"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1801847","DOI":"10.1002\/advs.201801847","article-title":"Emerging nano-\/microapproaches for cancer immunotherapy","volume":"6","author":"Mi","year":"2019","journal-title":"Adv Sci (Weinh)"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm059","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn0851","article-title":"T cells to fix a broken heart","volume":"375","author":"Gao","year":"2022","journal-title":"Science"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02623-x","article-title":"Boosting CAR T cells with anti-tumor mRNA vaccines","volume":"29","author":"Chehrazi-Raffle","year":"2023","journal-title":"Nat Med"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887125","article-title":"mRNA vaccines: the dawn of a new era of cancer immunotherapy","volume":"13","author":"Deng","year":"2022","journal-title":"Front Immunol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00017","article-title":"Thymus-derived, peripherally derived, and in vitro-induced T regulatory cells","volume":"5","author":"Elkord","year":"2014","journal-title":"Front Immunol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01517","article-title":"Engineering specificity and function of therapeutic regulatory T cells","volume":"8","author":"McGovern","year":"2017","journal-title":"Front Immunol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02359","article-title":"Chimeric antigen receptor (CAR) Treg: A promising approach to inducing immunological tolerance","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Immunol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.10.054","article-title":"A special population of regulatory T cells potentiates muscle repair","volume":"155","author":"Burzyn","year":"2013","journal-title":"Cell"},{"key":"B173","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1365-2567.2008.02813.x","article-title":"Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target","volume":"124","author":"Sojka","year":"2008","journal-title":"Immunology"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-653667","article-title":"Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect","volume":"127","author":"Brunstein","year":"2016","journal-title":"Blood"},{"key":"B178","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201142115","article-title":"TCR diversity and Treg cells, sometimes more is more","volume":"41","author":"Wing","year":"2011","journal-title":"Eur J Immunol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/biomedicines10020287","article-title":"CAR-T regulatory (CAR-Treg) cells: engineering and applications","volume":"10","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicines"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2012.09.006","article-title":"Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs","volume":"15","author":"Abou-El-Enein","year":"2013","journal-title":"Cytotherapy"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20060468","article-title":"Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells","volume":"203","author":"Seddiki","year":"2006","journal-title":"J Exp Med"},{"key":"B183","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflamm"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-019-0329-7","article-title":"One-step generation of modular CAR-T cells with AAV-Cpf1","volume":"16","author":"Dai","year":"2019","journal-title":"Nat Methods"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.180","article-title":"Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors","volume":"31","author":"Monjezi","year":"2017","journal-title":"Leukemia"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001278","article-title":"CD45RA distinguishes CD4+CD25+CD127-\/low TSDR demethylated regulatory T cell subpopulations with differential stability and susceptibility to tacrolimus-mediated inhibition of suppression","volume":"101","author":"Arroyo Hornero","year":"2017","journal-title":"Transplantation"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0041-4","article-title":"Next-generation regulatory T cell therapy","volume":"18","author":"Ferreira","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14415","article-title":"Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants","volume":"17","author":"Chandran","year":"2017","journal-title":"Am J Transplant"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0061-z","article-title":"Natural killer cells and other innate lymphoid cells in cancer","volume":"18","author":"Chiossone","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830050209","article-title":"Natural\u201d killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell","volume":"5","author":"Kiessling","year":"1975","journal-title":"Eur J Immunol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01179","article-title":"Killer Ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation","volume":"10","author":"Pende","year":"2019","journal-title":"Front Immunol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051143","article-title":"Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells","volume":"202","author":"Bryceson","year":"2005","journal-title":"J Exp Med"},{"key":"B194","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.molimm.2018.07.015","article-title":"Genome-wide analyses and functional profiling of human NK cell lines","volume":"115","author":"Gunesch","year":"2019","journal-title":"Mol Immunol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-015-8664-y","article-title":"Practical NK cell phenotyping and variability in healthy adults","volume":"62","author":"Angelo","year":"2015","journal-title":"Immunol Res"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.707542","article-title":"CAR-NK cells: from natural basis to design for kill","volume":"12","author":"Khawar","year":"2021","journal-title":"Front Immunol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/cmi.2014.91","article-title":"NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma","volume":"12","author":"Sun","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2015.41","article-title":"Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy","volume":"36","author":"Sun","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.2MR1218-501R","article-title":"Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy","volume":"105","author":"Wu","year":"2019","journal-title":"J Leukoc Biol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00808-3","article-title":"Advances in NK cell production","volume":"19","author":"Fang","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00329","article-title":"Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications","volume":"8","author":"Sarvaria","year":"2017","journal-title":"Front Immunol"},{"key":"B203","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3390\/cancers11060769","article-title":"Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy","volume":"11","author":"Lupo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00246-w","article-title":"Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany","volume":"28","author":"Albinger","year":"2021","journal-title":"Gene Ther"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01109","article-title":"CAR-T cells hit the tumor microenvironment: strategies to overcome tumor escape","volume":"11","author":"Rodriguez-Garcia","year":"2020","journal-title":"Front Immunol"},{"key":"B206","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.3390\/cancers14174318","article-title":"Current progress of CAR-NK therapy in cancer treatment","volume":"14","author":"Pang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B207","doi-asserted-by":"publisher","first-page":"861920","DOI":"10.1155\/bmri.v2011.1","article-title":"Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy","volume":"2011","author":"Meazza","year":"2011","journal-title":"J BioMed Biotechnol"},{"key":"B208","doi-asserted-by":"publisher","first-page":"5899","DOI":"10.3390\/ijms22115899","article-title":"CAR-NK cells in the treatment of solid tumors","volume":"22","author":"Wrona","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B209","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/CJI.0000000000000082","article-title":"Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12\/SDF-1yificedddcs glioblastoma","volume":"38","author":"M\u00fcller","year":"2015","journal-title":"J Immunother"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1629-5","article-title":"CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo","volume":"64","author":"Wennerberg","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-4622(02)00057-1","article-title":"Polybrene increases retrovirus gene transfer efficiency by enhancing receptor-independent virus adsorption on target cell membranes","volume":"97","author":"Davis","year":"2002","journal-title":"Biophys Chem"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0520-5","article-title":"Cancer-eating immune cells kitted out with CARs","volume":"38","author":"Dolgin","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00188","article-title":"Tumor-associated macrophages: recent insights and therapies","volume":"10","author":"Zhou","year":"2020","journal-title":"Front Oncol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1111\/febs.2018.285.issue-4","article-title":"The roles of CSFs on the functional polarization of tumor-associated macrophages","volume":"285","author":"Jeannin","year":"2018","journal-title":"FEBS J"},{"key":"B215","doi-asserted-by":"publisher","first-page":"697972","DOI":"10.1155\/2013\/697972","article-title":"Monocytes, peripheral blood mononuclear cells, and THP-1 cells exhibit different cytokine expression patterns following stimulation with lipopolysaccharide","volume":"2013","author":"Schildberger","year":"2013","journal-title":"Mediators Inflammation"},{"key":"B216","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000339044","article-title":"Impact of oxLDL and LPS on C-type natriuretic peptide system is different between THP-1 cells and human peripheral blood monocytic cells","volume":"30","author":"Bruckmeier","year":"2012","journal-title":"Cell Physiol Biochem"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03218-7","article-title":"NINJ1 mediates plasma membrane rupture during lytic cell death","volume":"591","author":"Kayagaki","year":"2021","journal-title":"Nature"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.v233.9","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Shapouri-Moghaddam","year":"2018","journal-title":"J Cell Physiol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"B220","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B221","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","article-title":"Tumor-associated macrophages: from basic research to clinical application","volume":"10","author":"Yang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B222","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cell.2022.02.021","article-title":"Tissue-resident FOLR2(+) macrophages associate with CD8(+) T cell infiltration in human breast cancer","volume":"185","author":"Nalio Ramos","year":"2022","journal-title":"Cell"},{"key":"B223","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","article-title":"Macrophage, the potential key mediator in CAR-T related CRS","volume":"9","author":"Hao","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"B224","doi-asserted-by":"publisher","first-page":"50323","DOI":"10.3791\/50323-v","article-title":"Investigation of macrophage polarization using bone marrow derived macrophages","volume":"23","author":"Ying","year":"2013","journal-title":"J Vis Exp"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2012.61","article-title":"Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein","volume":"20","author":"Bobadilla","year":"2013","journal-title":"Gene Ther"},{"key":"B226","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","article-title":"Tumor-associated macrophages: an accomplice in solid tumor progression","volume":"26","author":"Chen","year":"2019","journal-title":"J BioMed Sci"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.060","article-title":"Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice","volume":"134","author":"Elinav","year":"2008","journal-title":"Gastroenterology"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.049","article-title":"Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor","volume":"136","author":"Elinav","year":"2009","journal-title":"Gastroenterology"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B232","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00739-3","article-title":"Treat-to-target in systemic lupus erythematosus: advancing towards its implementation","volume":"18","author":"Parra S\u00e1nchez","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14175","article-title":"Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am J Transplant"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-022-00940-w","article-title":"Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease","volume":"44","author":"Richardson","year":"2022","journal-title":"Semin Immunopathol"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B239","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902592","article-title":"TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus","volume":"184","author":"Nickerson","year":"2010","journal-title":"J Immunol"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.03.008","article-title":"Personalized immunomonitoring uncovers molecular networks that stratify lupus patients","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015209","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin Immunol"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2019.12.009","article-title":"Toward an optimized process for clinical manufacturing of CAR-Treg cell therapy","volume":"38","author":"Fritsche","year":"2020","journal-title":"Trends Biotechnol"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00043","article-title":"Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity","volume":"10","author":"Romano","year":"2019","journal-title":"Front Immunol"},{"key":"B249","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jgg.2022.05.005","article-title":"Current status and perspectives of regulatory T cell-based therapy","volume":"49","author":"Qu","year":"2022","journal-title":"J Genet Genomics"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00832","article-title":"Human leukocyte antigen (HLA) and immune regulation: how do classical and non-classical HLA alleles modulate immune response to human immunodeficiency virus and hepatitis C virus infections","volume":"8","author":"Crux","year":"2017","journal-title":"Front Immunol"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14185","article-title":"Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am J Transplant"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000411","article-title":"Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice","volume":"3","author":"B\u00e9zie","year":"2019","journal-title":"Blood Adv"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.03.030","article-title":"Study design: human leukocyte antigen class I molecule A(leculeemour,c antigen receptor regulatory T cells in renal transplantation","volume":"7","author":"Schreeb","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2018-0075","article-title":"A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease","volume":"12","author":"Seyedian","year":"2019","journal-title":"J Med Life"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142242","article-title":"Type 1 diabetes mellitus: much progress, many opportunities","volume":"131","author":"Powers","year":"2021","journal-title":"J Clin Invest"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.060244","article-title":"Type 1 diabetes: pathogenesis and prevention","volume":"175","author":"Gillespie","year":"2006","journal-title":"Cmaj"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","journal-title":"Lancet"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31142-0","article-title":"Advances in technology for management of type 1 diabetes","volume":"394","author":"Beck","year":"2019","journal-title":"Lancet"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.05.004","article-title":"Human FoxP3+ regulatory T cells in systemic autoimmune diseases","volume":"10","author":"Miyara","year":"2011","journal-title":"Autoimmun Rev"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003099","article-title":"Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes","volume":"186","author":"McClymont","year":"2011","journal-title":"J Immunol"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.1.92","article-title":"Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes","volume":"54","author":"Lindley","year":"2005","journal-title":"Diabetes"},{"key":"B263","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2249.2007.03475.x","article-title":"Dynamic changes in CD4+ CD25+(high) T cell apoptosis after the diagnosis of type 1 diabetes","volume":"150","author":"Glisic-Milosavljevic","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.5.3053","article-title":"Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice","volume":"175","author":"Masteller","year":"2005","journal-title":"J Immunol"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.2.306","article-title":"Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes","volume":"54","author":"Jaeckel","year":"2005","journal-title":"Diabetes"},{"key":"B266","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92865","article-title":"T cells expressing chimeric antigen receptor promote immune tolerance","volume":"2","author":"Pierini","year":"2017","journal-title":"JCI Insight"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2389","article-title":"Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease","volume":"17","author":"Dominguez-Villar","year":"2011","journal-title":"Nat Med"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1038\/nature11581","article-title":"Novel Foxo1-dependent transcriptional programs control T(reg) cell function","volume":"491","author":"Ouyang","year":"2012","journal-title":"Nature"},{"key":"B271","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3432","article-title":"Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis","volume":"20","author":"Komatsu","year":"2014","journal-title":"Nat Med"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq237","article-title":"Numbers of CD25+Foxp3+ T cells that lack the IL-7 receptor are increased intra-articularly and have impaired suppressive function in RA patients","volume":"49","author":"van Roon","year":"2010","journal-title":"Rheumatol (Oxford)"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-017-0704-4","article-title":"Adoptive induced antigen-specific treg cells reverse inflammation in collagen-induced arthritis mouse model","volume":"41","author":"Sun","year":"2018","journal-title":"Inflammation"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.12.018","article-title":"Biological drug and drug delivery-mediated immunotherapy","volume":"11","author":"Xiao","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.934343","article-title":"Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges","volume":"13","author":"Riet","year":"2022","journal-title":"Front Immunol"},{"key":"B277","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3390\/medicina57101080","article-title":"An updated review of pemphigus diseases","volume":"57","author":"Malik","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.1522","article-title":"Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients","volume":"148","author":"Lunardon","year":"2012","journal-title":"Arch Dermatol"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.172","article-title":"Rituximab exerts a dual effect in pemphigus vulgaris","volume":"128","author":"Eming","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B280","doi-asserted-by":"publisher","first-page":"175ra30","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1519671\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T01:10:51Z","timestamp":1736385051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1519671\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":280,"alternative-id":["10.3389\/fimmu.2024.1519671"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1519671","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"article-number":"1519671"}}